Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ITI-214.

Key facts

Study ID

NCT03257046

Run by

Intra-Cellular Therapies, Inc.

People needed

40

Starts

2017-09-28

Expected to finish

2018-09-28

Last updated by the study team

2018-12-20

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• Duke Early Phase Research Unit — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.